Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of MOLBREEVI BLA, a treatment for pulmonary alveolar proteinosis [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1] - Unlikelihood of FDA approval for MOLBREEVI BLA in its current form [1] - Delay in submission of MOLBREEVI BLA within the previously represented timeframe [1] - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1] - Overall, public statements made by the defendants were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of SVRA during the specified timeframe are encouraged to register for the class action by November 7, 2025, to potentially become lead plaintiffs [2]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].